Juan Chi-Chang, Shen Yi-Wen, Chien Yueh, Lin Yen-Jie, Chang Shau-Feng, Ho Low-Tone
Institutes of Physiology and Clinical Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China.
Am J Physiol Endocrinol Metab. 2004 Nov;287(5):E948-54. doi: 10.1152/ajpendo.00536.2003. Epub 2004 Jun 29.
We previously showed that chronic insulin infusion induces insulin resistance, hyperendothelinemia, and hypertension in rats (C. C. Juan, V. S. Fang, C. F. Kwok, J. C. Perng, Y. C. Chou, and L. T. Ho. Metabolism 48: 465-471, 1999). Endothelin-1 (ET-1), a potent vasoconstrictor, is suggested to play an important role in maintaining vascular tone and regulating blood pressure, and insulin increases ET-1 production in vivo and in vitro. In the present study, BQ-610, a selective endothelin A receptor antagonist, was used to examine the role of ET-1 in insulin-induced hypertension in rats. BQ-610 (0.7 mg/ml; 0.5 ml/kg body wt) or normal saline was given intraperitoneally two times daily for 25 days to groups of rats infused with either saline or insulin (2 U/day via sc-implanted osmotic pumps), and changes in plasma levels of insulin, glucose, and ET-1 and the systolic blood pressure were measured over the experimental period, whereas changes in insulin sensitivity were examined at the end of the experimental period. Plasma insulin and ET-1 levels were measured by RIA, plasma glucose levels using a glucose analyzer, systolic blood pressure by the tail-cuff method, and insulin sensitivity by an oral glucose tolerance test. Our studies showed that insulin infusion caused sustained hyperinsulinemia in both saline- and BQ-610-injected rats over the infusion period. After pump implantation (2 wk), the systolic blood pressure was significantly higher in insulin-infused rats than in saline-infused rats in the saline-injected group (133 +/- 3.1 vs. 113 +/- 1.1 mmHg, P < 0.05) but not in the BQ-610-injected group (117 +/- 1.2 vs. 117 +/- 1.8 mmHg). Plasma ET-1 levels in both sets of insulin-infused rats were higher than in saline-infused controls (2.5 +/- 0.6 and 2.5 +/- 0.8 vs. 1.8 +/- 0.4 and 1.7 +/- 0.3 pmol/l, P < 0.05). Oral glucose tolerance tests showed that BQ-610 treatment did not prevent the insulin resistance caused by chronic insulin infusion. No significant changes were found in insulin sensitivity and blood pressure in saline-infused rats treated with BQ-610. In a separate experiment, insulin infusion induced the increase in arterial ET-1 content, hypertension, and subsequent plasma ET-1 elevation in rats. These results suggest that, in the insulin infusion rat model, ET-1 plays a mediating role in the development of hypertension, but not of insulin resistance.
我们先前的研究表明,慢性胰岛素输注可诱导大鼠出现胰岛素抵抗、高内皮素血症和高血压(C.C. Juan、V.S. Fang、C.F. Kwok、J.C. Perng、Y.C. Chou和L.T. Ho。《新陈代谢》48: 465 - 471, 1999)。内皮素 - l(ET - 1)是一种强效血管收缩剂,被认为在维持血管张力和调节血压方面发挥重要作用,并且胰岛素可在体内和体外增加ET - 1的生成。在本研究中,使用选择性内皮素A受体拮抗剂BQ - 610来研究ET - 1在胰岛素诱导的大鼠高血压中的作用。将BQ - 610(0.7 mg/ml;0.5 ml/kg体重)或生理盐水每天腹腔注射两次,持续25天,分别给予输注生理盐水或胰岛素(通过皮下植入渗透泵,每天2 U)的大鼠组,在实验期间测量血浆胰岛素、葡萄糖和ET - 1水平以及收缩压的变化,而在实验期末检查胰岛素敏感性的变化。采用放射免疫分析法测定血浆胰岛素和ET - 1水平,使用葡萄糖分析仪测定血浆葡萄糖水平,采用尾套法测定收缩压,通过口服葡萄糖耐量试验测定胰岛素敏感性。我们的研究表明,在输注期间,胰岛素输注在注射生理盐水和BQ - 610的大鼠中均导致持续的高胰岛素血症。在植入泵后(2周),在注射生理盐水的组中,胰岛素输注大鼠的收缩压显著高于输注生理盐水的大鼠(133±3.1 vs. 113±1.1 mmHg,P<0.05),但在注射BQ - 610的组中无显著差异(117±1.2 vs. 117±1.8 mmHg)。两组胰岛素输注大鼠的血浆ET - 1水平均高于输注生理盐水的对照组(2.5±0.6和2.5±0.8 vs. 1.8±0.4和1.7±0.3 pmol/l,P<0.05)。口服葡萄糖耐量试验表明,BQ - 610治疗不能预防慢性胰岛素输注引起的胰岛素抵抗。注射BQ - 610的输注生理盐水大鼠的胰岛素敏感性和血压无显著变化。在另一项实验中,胰岛素输注诱导大鼠动脉ET - 1含量增加、高血压以及随后的血浆ET - 1升高。这些结果表明在胰岛素输注大鼠模型中,ET - 1在高血压的发生中起介导作用,但在胰岛素抵抗的发生中不起作用。